as of february 2019, relugolix is in phase iii clinical trials for endometriosis and prostate cancer. it was approved for use for the treatment of uterine fibroids in japan in january 2019. a new drug application of relugolix for uterine fibroids is expected to be submitted in the united states late 2019.